Detection of Minimal Residual Disease in Leukemic Patients.
スポンサーリンク
概要
- 論文の詳細を見る
Much progress has been made in the therapy of neoplastic patients in this decade. Amongst prognosis of childhood ALL has been improved remarkably. However, some patients recur despite well-programmed therapies. This might be partly due to the abscence of any information for minimal residual disease (MRD). It has been difficult to effectively monitor the MRD because they are extremely small in number once the patients achieve complete remission. Recently polymerase chain reaction (PCR) has opened a new avenue toward much better diagnosis of MRD. Tumor specific sequences derived from chromosomal translocations or recombination of immunoglobulin or T cell receptor genes are PCR-amplified in 10<SUP>4</SUP> to 10<SUP>6</SUP> folds in several hours. Currently we are examining MRD in the ALL patients who are treated under the protocols of Children's Cancer and Leukemia Study Group (CCLSG) using TCR δ gene recombination as a clonal marker. The details of the system and part of the results are mentioned in this article.
- 特定非営利活動法人 日本小児血液・がん学会の論文
特定非営利活動法人 日本小児血液・がん学会 | 論文
- The Parent's Emotional Adaptation to the Children's Malignant Disease
- Side Effect of Cranial Radiation in Childhood Acute Leukemia
- Red Blood Cell Volume Distribution Width in Normal Children and in the Patients with Various Kinds of Hematological Disorders.
- Effective Conditioning of Donors for Granulocyte Transfusions with Recombinant Human Granulocyte Colony-Stimulating Factor.
- Two Infant Girls of CNS Leukemia with Chronic Subdural Hematoma